Prazosin
As of the edition of 20 October 2026, Prazosin is a small molecule: marketed, first approved in 1979 (ES); acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Minipress
- First approved
- 1 December 1979 (ES)
- Approvals on record
- 13 in 4 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 40, 6 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system; Heart and blood vessels; Digestive system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Prazosin.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 7 | 0 | 4 |
| Phase 1 | 6 | 5 | 0 | 0 |
| Phase 2 | 12 | 8 | 3 | 1 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 8 | 6 | 0 | 1 |
| All trials | 40 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 2021 to now |